Streetbeat News

Analyst Ratings

TRGP

Goldman Sachs analyst John Mackay has maintained a Buy rating on Targa Resources (NYSE:TRGP) and increased the price target from $105 to $117.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:02 pm

AVY

Citigroup analyst Anthony Pettinari maintains a Neutral rating on Avery Dennison (AVY) and raises the price target from $223 to $234.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:01 pm

NMIH

NMI Holdings (NASDAQ:NMIH) has been evaluated by 5 analysts over the last three months, showing diverse opinions from bullish to bearish. Recent updates include raised price targets, with an average 12-month target of $34.8, marking a 5.45% increase from the previous average of $33. The company's financial performance is strong, with notable revenue growth, high net margin, and excellent ROE and ROA, positioning it above industry averages.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:01 pm

MGNX

Analyst ratings for Macrogenics (NASDAQ:MGNX) have shown a diverse range of opinions, with recent updates indicating a positive shift. Over the past quarter, 10 analysts have provided ratings, with a notable increase in the 12-month price target to $21.8, up 48.3% from the previous $14.70. This adjustment reflects optimism based on the company's potential, despite challenges in revenue growth and financial metrics. Macrogenics, a biotech firm focusing on cancer therapeutics, has seen its market position and financial performance analyzed, revealing areas of concern such as a significant revenue decline and below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:01 pm

BV

Brightview Holdings Inc (NYSE:BV) shares fell after a recent surge, due to a downgrade by Goldman Sachs from Neutral to Sell, despite a price target increase from $8 to $10. The downgrade is based on the company's strategy to exit low-margin contracts, which is expected to negatively impact revenues, especially in its landscape maintenance business. Additionally, a warmer 2023-2024 winter is anticipated to reduce snow removal revenue, further challenging the company's financial outlook.

Portfolio Pulse from Priya Nigam

April 04, 2024 | 4:00 pm

BAC

Bank of America (NYSE:BAC) received mixed analyst ratings with a shift towards a more cautious stance in the last 30 days. The average 12-month price target is $40.99, reflecting a 1.71% increase from the previous target. Analysts from firms like UBS, Wells Fargo, and HSBC adjusted their price targets, indicating a nuanced view of the bank's future performance. Despite these adjustments, Bank of America faces challenges in revenue growth, net margin, ROE, and ROA, suggesting potential hurdles ahead.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:00 pm

BFH

Bread Finl Hldgs (NYSE:BFH) has been analyzed by 7 analysts, showing a shift towards a more positive outlook with an average 12-month price target of $38.29, up 18.43% from the previous $32.33. Analyst actions range from 'Outperform' to 'Underweight', reflecting diverse perspectives on the company's performance. Bread Financial, known for its credit card and loyalty program services, faces challenges in revenue growth and efficiency metrics but maintains a strong net margin.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:00 pm

STAA

Staar Surgical (NASDAQ:STAA) has been evaluated by 4 analysts over the last three months, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $44.5, reflecting a 4.71% increase from the previous $42.50. Analyst actions include maintaining, raising, and lowering ratings and price targets. Staar Surgical, a manufacturer of implantable lenses, has shown solid revenue growth of 19.09% as of December 31, 2023, with a net margin of 10.17% and exceptional ROE and ROA, indicating strong financial health.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:00 pm

PRIM

Goldman Sachs analyst Jerry Revich has maintained a Neutral rating on Primoris Services (PRIM) and increased the price target from $38 to $43.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:00 pm

AYI

Goldman Sachs analyst Brian Lee maintains a Neutral rating on Acuity Brands (NYSE:AYI) and raises the price target from $227 to $261.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 3:57 pm